Game-Changing Cancer Therapy: Gold Nanorods +…
0 reactions
Game-Changing Cancer Therapy: Gold Nanorods + Immunotherapy Wipe Out Tumors in Preclinical Study – 38% Complete Remission in Hard-to-Treat Colorectal Cancer
This is the kind of story that gives you real hope for the future of cancer treatment.
Sona Nanotech's Targeted Hyperthermia Therapy (THT) uses tiny gold nanorods that get injected into tumors and then gently heated with near-infrared light. When they combined it with standard immunotherapy in a recent preclinical study on "cold" colorectal cancer (the stubborn kind that usually ignores immunotherapy), the results were impressive.
In the study, published in the Journal of Nanobiotechnology, 100% of the animals that got the combo showed a response to immunotherapy compared to basically zero with immunotherapy alone. Even better, 38% of them (8 out of 21) had their tumors completely disappear by day 24 and stayed cancer-free for the entire 45-day study period.
This builds on their earlier positive results in melanoma and breast cancer models, and they already have early human safety data from melanoma patients. The researchers think this approach could help turn "cold" tumors hot so the immune system can finally attack them effectively.
It's still early (preclinical), but it's a smart, minimally invasive way to potentially make immunotherapy work for a lot more people, including the growing number of younger adults getting colon cancer. Science keeps delivering these small but meaningful wins!
#inspiration
This is the kind of story that gives you real hope for the future of cancer treatment.
Sona Nanotech's Targeted Hyperthermia Therapy (THT) uses tiny gold nanorods that get injected into tumors and then gently heated with near-infrared light. When they combined it with standard immunotherapy in a recent preclinical study on "cold" colorectal cancer (the stubborn kind that usually ignores immunotherapy), the results were impressive.
In the study, published in the Journal of Nanobiotechnology, 100% of the animals that got the combo showed a response to immunotherapy compared to basically zero with immunotherapy alone. Even better, 38% of them (8 out of 21) had their tumors completely disappear by day 24 and stayed cancer-free for the entire 45-day study period.
This builds on their earlier positive results in melanoma and breast cancer models, and they already have early human safety data from melanoma patients. The researchers think this approach could help turn "cold" tumors hot so the immune system can finally attack them effectively.
It's still early (preclinical), but it's a smart, minimally invasive way to potentially make immunotherapy work for a lot more people, including the growing number of younger adults getting colon cancer. Science keeps delivering these small but meaningful wins!
#inspiration
| 2,000 mlx | |
| 3 | |
| 0 |